55 patents
Utility
Compositions and methods for inhibition of the JAK pathway
28 Nov 23
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
Filed: 2 Nov 21
Utility
RIP1K inhibitors
21 Feb 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Ihab Darwish, Zhushou Luo, Vanessa Taylor
Filed: 2 Apr 21
Utility
Heterocyclic RIP1 inhibitory compounds
14 Feb 23
Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
Filed: 6 Nov 20
Utility
RIP1 inhibitory compounds and methods for making and using the same
31 Jan 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Jiaxin Yu, Ihab Darwish, Vanessa Taylor, Rao Kolluri, Yan Chen, Simon Shaw, Somasekhar Bhamidipati, Zhushou Luo
Filed: 4 Sep 20
Utility
Amide compounds and method for making and using
20 Dec 22
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors.
Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
Filed: 24 Feb 21
Utility
2,4-diamino-pyrimidine compounds and method for making and using the compounds
13 Dec 22
Yan Chen, Rose Yen, Jiaxin Yu, Vanessa Taylor, Rajinder Singh
Filed: 5 Jun 20
Utility
IRAK inhibitors and method for making and using
8 Nov 22
Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors.
Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
Filed: 24 Feb 21
Utility
Heterocyclic RIP1 kinase inhibitors
25 Oct 22
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor
Filed: 4 Sep 20
Utility
RIP1 inhibitory compounds and methods for making and using the same
18 Oct 22
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 16 Oct 20
Utility
TGF-β inhibitors
11 Oct 22
Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
Filed: 2 Nov 20
Utility
RIP1 inhibitory compounds and methods for making and using the same
9 Aug 22
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
Filed: 4 Sep 20
Utility
RIP1 inhibitory compounds and methods for making and using the same
5 Jul 22
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 16 Sep 20
Utility
TGF-beta inhibitors
7 Jun 22
Todd Kinsella, Marina Gelman, Hui Hong, Ihab S. Darwish, Rajinder Singh, Jiaxin Yu, Robert M. Borzilleri, Upender Velaparthi, Peiying Liu, Chetan Padmakar Dame, Hasibur Rahaman, Jayakumar Sankara Warrier
Filed: 21 Mar 19
Utility
RIP1 inhibitory compounds and methods for making and using the same
17 May 22
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 16 Sep 20
Utility
Nrf2 activating compounds and uses thereof
22 Mar 22
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 20 Oct 20
Utility
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
25 Jan 22
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases.
Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
Filed: 21 Mar 19
Utility
Compounds and method for treating autoimmune diseases
11 Jan 22
Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
Filed: 26 Aug 19
Utility
Compositions and methods for inhibition of the JAK pathway
14 Dec 21
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
Filed: 26 Aug 19
Utility
Compositions and methods for inhibition of the JAK pathway
16 Nov 21
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
Filed: 17 Oct 19
Utility
Direct AMPK activators
16 Nov 21
Simon Shaw, Xiang Xu, Sarkiz Issakani, Rajinder Singh, Yasumichi Hitoshi, Matthew Duncton, Nan Lin
Filed: 15 Aug 17